NCT04412772 (ARCHITECTS) is a Phase 3 clinical trial of Tocilizumab in COVID-19, sponsored by Queen's Medical Center.

Who is sponsoring NCT04412772?

NCT04412772 is sponsored by Queen's Medical Center.

What drugs are being tested in NCT04412772?

Interventions in NCT04412772: Tocilizumab, Placebo.

Is NCT04412772 still recruiting?

NCT04412772 is currently terminated. Last updated 10 February 2026.

Last reviewed 2026-02-10 · How we verify

NCT04412772: ARCHITECTS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS

Terminated Phase 3 Last updated 10 February 2026

What this trial tests

Phase 3 trial testing Tocilizumab in COVID-19 in 20 participants. Terminated before completion.

Timeline

12 June 2020

Primary endpoint
31 March 2021

31 March 2021

Quick facts

Lead sponsor	Queen's Medical Center
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	20
Start date	12 June 2020
Primary completion	31 March 2021
Estimated completion	31 March 2021
Sites	1 location across United States

Drugs / interventions tested

Tocilizumab (tocilizumab) — full drug profile →
Placebo

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Queen's Medical Center

Who can join

Adults 18 to 95, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall objective is to evaluate the clinical efficacy and safety of tocilizumab relative to placebo among approximately 300 hospitalized adult patients who have severe COVID-19. The study will be a 2 arm double blinded comparison between tocilizumab 8 mg/kg and matching placebo IV. The dose may be repeated in 8-12 hours if clinical symptoms worsens, (e.g. increase in oxygen requirements). Participants will be followed for 28 days.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CL, Godolphin PJ, et al · · 2021 · cited 548× · PMID 34228774 · DOI 10.1001/jama.2021.11330
COVID-19 and Cancer: Current Challenges and Perspectives.
Bakouny Z, Hawley JE, Choueiri TK, Peters S, et al · · 2020 · cited 201× · PMID 33049215 · DOI 10.1016/j.ccell.2020.09.018
COVID-19: Characteristics and Therapeutics.
Chilamakuri R, Agarwal S. · · 2021 · cited 192× · PMID 33494237 · DOI 10.3390/cells10020206
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Platelet and Endothelial Activation as Potential Mechanisms Behind the Thrombotic Complications of COVID-19 Patients.
Canzano P, Brambilla M, Porro B, Cosentino N, et al · · 2021 · cited 170× · PMID 33649738 · DOI 10.1016/j.jacbts.2020.12.009
Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
Ghosn L, Chaimani A, Evrenoglou T, Davidson M, et al · · 2021 · cited 119× · PMID 33734435 · DOI 10.1002/14651858.cd013881
Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm.
Pum A, Ennemoser M, Adage T, Kungl AJ. · · 2021 · cited 70× · PMID 33445810 · DOI 10.3390/biom11010091
SARS coronavirus 2: from genome to infectome.
Rastogi M, Pandey N, Shukla A, Singh SK. · · 2020 · cited 69× · PMID 33261606 · DOI 10.1186/s12931-020-01581-z

Verify or expand the search:

Other trials of Tocilizumab

Trials testing the same drug.

NCT03787290 — Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder · Phase 2 · suspended
NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting
NCT06016517 — Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis · not yet recruiting
NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Queen's Medical Center trials

Trials by the same sponsor.

NCT06931197 — Why Wait? Initiating Contingency Management in Traumatically Injured Patients During Hospitalization · NA · not yet recruiting
NCT06933381 — Vapocoolant Spray to Reduce Pain With Nexplanon Insertion · NA · recruiting
NCT06951438 — Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortio · NA · recruiting
NCT06532370 — Implementing a Contingency Management Program Addressing Methamphetamine Use For and With the People of Hawaii · NA · recruiting
NCT06529003 — TENS Unit To Decrease Pain After Laminaria Insertion · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04412772 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Queen's Medical Center
Last refreshed: 10 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04412772.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing